Members of a consensus committee formed to address the care of those on long-term, high-dose opioids, especially “legacy patients,” will discuss methods and ethics of compassionate management with extensive audience participation. Criteria for maintaining vs. weaning, opioid use “gray zones,” the role of buprenorphine, i.a., will be discussed.
This is a non-CME event.
AAPM Foundation Opioid Reduction Consensus Project Introduction
Charles Argoff, MD
High Dose Patients: Taper or Maintain?
What Should Be Done About Dangerous Combinations
Michael Hooten, MD
When Is Referral Actually Abandonment
Continue or Curtail, Consensual or Coercive: Who Decides?
How to Taper
Complex Persistent Dependence
Jane Ballantyne, MD FRCA
Fiscal Responsibility Versus Duties as Healers
Steven Stanos, DO
A Balancing Act: Tools to Help Taper
Jennifer Murphy, PhD
- Determine whether and how to reduce opioids.
- Develop and implement a plan for comfortable opioid and sedative reduction.
- Effectively manage those who, despite no opioid use disorder, respond poorly to both opioid escalation and reduction.
- AJOVY® (fremanezumab-vfrm) Injection: An anti-CGRP for the Preventive Treatment of Migraine in Adults
- Applying to Pain Fellowships, Maximize Your Success: Tips for a Successful Match and Beyond (317)
- Going Deeper into Opioid Deprescribing: Addressing the Concerns of Prescribers and Patients to Optimize Outcomes (302)
- Opioid Therapy 2020: Past, Present, and Future (306)
- The Future of IPM? Evidence, Technique, Documentation, Billing and Coding Strategies for Percutaneous Surgeries (318)